Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Targeting sustainable revenue growth of 25% to 30% CAGR over the next 3-5 years (Page 9, 15). Senores Pharmaceuticals targets a medium-term revenue growth of over 25% annually.
From Senores Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Targeting sustainable revenue growth of 25% to 30% CAGR over the next 3-5 years (Page 9, 15).
- Regulated markets expected to contribute around 65% of revenue going forward (Page 9).
- Emerging markets projected to achieve double-digit growth starting FY'27 (Page 12).
- New product launches planned every quarter for next 4-5 quarters, boosting regulated market sales and margins (Page 18).
- API facility in Chhatral expected to be FDA-approved in FY'27, supporting backward integration and supply chain stability, with incremental revenue of INR 50-100 crores from FY'27 (Page 9).
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New API facility in Chhatral expected to be completed and receive US FDA approval in FY'27.
- Targeted revenue from the API facility in FY'27 is INR 50-100 crores, primarily for backward integration and supply chain protection.
- Plan to use the API facility to integrate the supply chain for key products, enhancing vertical integration.
- Capacity expansion in the US manufacturing facility from INR 1.2 billion to INR 2 billion planned for FY'27.
- Continuous evolution of strategy with potential future investments as the company grows over the next 3-4 years.
2 more points from Senores Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Senores Pharmaceuticals has about $12 million worth of visible business for the year on the CDMO-CMO side across various contracts and customers (Page 12).
- The company expects a multi-fold growth in the CDMO-CMO segment with a potential CAGR of around 30% over the next 3 to 5 years (Page 12).
- Manufacturing capacities are pre-sold, and the company does not hold finished goods inventory; anything produced is already sold (Page 20).
2 more points from Senores Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹175 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wanbury Ltd (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q2 FY26)
42.35 crore, up 21.98% year-on-year from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q2 FY26 investor presentation — and how it ran
- Caplin Point Laboratories Ltd (Q2 FY26)
After 2 years, operating margins could improve to around 40%, if markets remain favorable. Key concall takeaways from Caplin Point Laboratories Ltd's Q2 FY26…
- Indoco Remedies Ltd (Q2 FY26)
R&D spend will reduce from ~5% to ~4% of sales, focusing on vertically integrated, higher efficiency products. Key concall takeaways from Indoco Remedies Ltd's…
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q2 FY26 results?
Targeting sustainable revenue growth of 25% to 30% CAGR over the next 3-5 years (Page 9, 15). Senores Pharmaceuticals targets a medium-term revenue growth of over 25% annually.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 48.0 with a market cap of ₹6,071 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
New API facility in Chhatral expected to be completed and receive US FDA approval in FY'27.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.